Clinical Trial Update: PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is investigating PSMA-PET radiomic biomarkers to predict progression and treatment response in prostate cancer, and the study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) | Conditions: Prostate Cancer | Phase 3 | Status: RECRUITING